Brain Damage, Chronic: Clinical Trials

95 trials for Brain Damage, Chronic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 completed, 25 unknown, 5 withdrawn, 4 recruiting. 95 Phase 2, 22 Phase 1, 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 295Completed 53, Unknown 25, Withdrawn 5, Recruiting 4, Active not recruiting 3, Terminated 3, Not yet recruiting 1, Suspended 1
Phase 122Completed 16, Unknown 3, Withdrawn 2, Active not recruiting 1
Phase 312Unknown 5, Completed 3, Recruiting 2, Terminated 1, Withdrawn 1

Follow Brain Damage, Chronic: new trials by email Literature Review of Brain Damage, Chronic trials Research Report on Brain Damage, Chronic

Trials (filtered) newest first · largest first

All 95 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilities
Extended Reality Exergaming - Cerebral Palsy (CP)
Phase 2Not yet recruitingUniversity of Alabama at Birmingham1302026-12-012026-05-14
Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy
Smart Ankle-Foot Orthosis, 5-Azacitidine, Placebo - Cerebral Palsy
Phase 2RecruitingShirley Ryan AbilityLab602026-05-282026-06-01
tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy
tSCS, 5-Azacitidine, Mannitol - Cerebral Palsy
Phase 2RecruitingShirley Ryan AbilityLab802026-05-282026-05-29
Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy
Magnetic Spinal Stimulation - Spastic Cerebral Palsy, Dysarthria
Phase 2 / Phase 3UnknownSociedad Argenttina de Neuromodulación202024-11-182023-11-21
Promoting Upright Mobility in Infants With Cerebral Palsy Using a Robotic Unweighting System
BabyG - Cerebral Palsy, Physical Therapy Modalities
Phase 2WithdrawnNational Institutes of Health Clinical Center (CC)2024-09-112025-08-05
Wereables for Upper Limb Functionality in Hemiparesis
WeFun-wearable activated, WeFun-wearable desactivated - Unilateral Cerebral Palsy
Phase 2 / Phase 3RecruitingUniversidade da Coruña402024-06-072025-03-12
Upper Limb Somatosensory Discrimination Therapy and Dose-matched Motor Therapy in Children and Adolescents With Unilateral Cerebral Palsy
Upper limb somatosensory discrimination therapy, Upper limb motor therapy - Cerebral Palsy, Spastic, Hemiplegic Cerebral Palsy
Phase 2UnknownHilde Feys502023-12-092024-02-07
Metformin for Motor and Cognitive Improvement in Children With Cerebral Palsy: A Feasibility Study
Metformin - Cerebral Palsy
Phase 2CompletedHolland Bloorview Kids Rehabilitation Hospital32023-11-142026-03-02
Spinal Cord Innovation in Pediatrics (SCiP) to Treat SensoriMotor Function in Children Cerebral Palsy: Protocol for a Randomized Controlled Trial
SCiP - Cerebral Palsy
Phase 2UnknownSpineX Inc.602023-09-012023-02-09
Therapeutic Photobiomodulation and Tretament of Spasticity
Photobiomodulation, Institution's Standard Physiotherapy, Photobiomodulation Placebo - Muscle Spasticity, Cerebral Palsy
Phase 2 / Phase 3CompletedUniversity of Nove de Julho122023-08-152026-05-01
Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries
Magnesium sulfate loading with maintenance dose, Magnesium sulfate loading dose only - Premature Birth, NEUROPROTECTION
Phase 2 / Phase 3UnknownZagazig University3362023-01-202023-07-14
ADX-629 Therapy for Sjogren-Larsson Syndrome
ADX-629 - Sjogren-Larsson Syndrome
Phase 1 / Phase 2CompletedUniversity of Nebraska82023-01-022026-05-05
INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)
IncobotulinumtoxinA 100 UNT [Xeomin] - Spastic Cerebral Palsy
Phase 2UnknownUniversita di Verona302022-06-012022-04-22
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Durvalumab - Early Small (cT1N0) Triple Negative Breast Cancer
Phase 2Active not recruitingGustave Roussy, Cancer Campus, Grand Paris2002021-12-062026-08-05
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident
Phase 2 / Phase 3TerminatedSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC322021-11-022026-05-27
Stem Cell and Conditioned Medium for Cerebral Palsy
Umbilical Cord Mesenchymal Stem Cells, Conditioned Medium, Standard Therapy - Cerebral Palsy
Phase 1 / Phase 2Active not recruitingPT. Prodia Stem Cell Indonesia782021-10-132026-02-25
Peripheral Modulation of Muscle Stiffness and Spasticity
Hyaluronidase, Placebo - Muscle Spasticity
Phase 2Active not recruitingJohns Hopkins University562021-10-112026-06-30
Apomorphine in Severe Brain-injured Patients
Apomorphine Hydrochloride 5mg/ml, Sodium chloride 9mg/ml - Disorder of Consciousness
Phase 2 / Phase 3RecruitingUniversity of Liege482021-06-182025-04-15
A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy
UDI-001 - Cerebral Palsy, Periventricular Leukomalacia
Phase 1 / Phase 2CompletedRohto Pharmaceutical Co., Ltd.62021-06-022025-04-06
Treatment of Children With Cerebral Palsy With Autologous Umbilical Cord Blood, a Pilot Study
Autologous umbilical cord blood transfusion, placebo - Cerebral Palsy
Phase 2UnknownSheba Medical Center722020-07-082021-01-20

Showing 20 of 95. Sign in to see all of them.

Narrower conditions

Cerebral Palsy (78)  ·  Muscle Spasticity (11)  ·  Persistent Vegetative State (10)  ·  Brain Injuries, Traumatic (9)  ·  Brain Injuries (6)  ·  Consciousness Disorders (6)  ·  Stroke (6)  ·  Paresis (5)  ·  Chronic Traumatic Encephalopathy (4)  ·  Brain Injury, Chronic (3)  ·  Amyotrophic Lateral Sclerosis (2)  ·  Coma (2)  ·  Dystonia (2)  ·  Hypoxia-Ischemia, Brain (2)  ·  Intracranial Hemorrhages (2)

Broader conditions

Brain Diseases (95)  ·  Central Nervous System Diseases (95)  ·  Nervous System Diseases (95)  ·  Pathological Conditions, Signs and Symptoms (43)  ·  Signs and Symptoms (36)  ·  Neurologic Manifestations (32)  ·  Wounds and Injuries (18)  ·  Craniocerebral Trauma (17)  ·  Trauma, Nervous System (17)  ·  Neurobehavioral Manifestations (15)  ·  Mental Disorders (13)  ·  Muscular Diseases (13)  ·  Pathologic Processes (13)  ·  Musculoskeletal Diseases (12)

Interventions

Botulinum Toxins, Type A (5)  ·  Sodium Chloride (4)  ·  Standard of Care (4)  ·  Apomorphine (3)  ·  Granulocyte Colony-Stimulating Factor (3)  ·  Saline Solution (3)  ·  incobotulinumtoxinA (3)  ·  7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (2)  ·  Acupuncture Therapy (2)  ·  Azacitidine (2)  ·  Baclofen (2)  ·  Constraint Induced Movement Therapy (2)  ·  Hyperbaric Oxygenation (2)  ·  Mannitol (2)  ·  Physical Therapy Modalities (2)

Sponsors

Bundang CHA Hospital (3)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (3)  ·  University of Liege (3)  ·  Hanyang University Seoul Hospital (2)  ·  Holland Bloorview Kids Rehabilitation Hospital (2)  ·  Joanne Kurtzberg, MD (2)  ·  National Institutes of Health Clinical Center (CC) (2)  ·  Shirley Ryan AbilityLab (2)  ·  State-Financed Health Facility "Samara Regional Medical Center Dinasty" (2)  ·  University of Calgary (2)  ·  University of Oklahoma (2)  ·  University of Southern California (2)  ·  Vinmec Healthcare System (2)  ·  Virginia Polytechnic Institute and State University (2)  ·  Agency for Healthcare Research and Quality (AHRQ) (1)

Countries

United States (39)  ·  South Korea (6)  ·  Belgium (5)  ·  Canada (4)  ·  Russia (4)  ·  Egypt (3)  ·  Israel (3)  ·  Spain (3)  ·  Vietnam (3)  ·  China (2)  ·  France (2)  ·  Iran (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Hong Kong (1)

Top investigators

Minyoung Kim, M.D., Ph.D. (3)  ·  Charles S Cox, MD (2)  ·  Darcy Fehlings, MD, MSc (2)  ·  Diane L Damiano, Ph.D. (2)  ·  Joanne Kurtzberg, MD (2)  ·  Liem T Nguyen, MD., PhD. (2)  ·  Steven Laureys, M.D., Ph.D. (2)  ·  Adam Kirton, MD MSc FRCPC (1)  ·  Adam Kirton, MD, MSc (1)  ·  Ahmed M Kamel, M.D. (1)  ·  Alexander A Ostanin, MD, PhD (1)  ·  Ali Reza Moaeidi, MD (1)  ·  Ali Reza Zali, MD (1)  ·  Amirali Hamidieh, MD (1)

Results publications

PMID 38114596, PMID 28403842, PMID 28688787, PMID 12529557, PMID 15037681, PMID 16108461, PMID 18065878, PMID 18676556, PMID 18990048, PMID 19416339, PMID 19811515, PMID 22071153, PMID 22541308, PMID 22747635, PMID 22776958, PMID 23106988, PMID 24100132, PMID 24607242, PMID 24909743, PMID 24969309, PMID 25113573, PMID 25157725, PMID 25534356, PMID 25593079, PMID 25863661, PMID 26745476, PMID 27029628, PMID 27187300, PMID 27927938, PMID 28109298, PMID 28867665, PMID 29080265, PMID 30107811, PMID 30782701, PMID 30941094, PMID 30969506, PMID 31438885, PMID 34362453, PMID 34484101, PMID 34649982, PMID 35351020, PMID 35811372, PMID 36477478, PMID 37555886, PMID 37564370, PMID 38087394, PMID 38409060, PMID 39624459, PMID 42156830, PMID 905874

NIH funding

2005 (1), P50AT000008 (1), R21AR051564 (1), R21HD054697 (1)